PRMT5 and neoplasm: Because the difference in inhibitory effects of these PRMT5 inhibitors from normal cells is as small as approximately two times compared to NDRG2low tumour cells, we are also encouraged to develop selective and efficient inhibitors targeting phosphorylated PRMT5 or adaptor protein binding sites such as MEP50, rather than protein-substrate and SAM-binding sites.